Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074878 · ClinicalTrials.gov registry record · Phase 1
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
A Phase 1 study, sponsored by Mothaffar Rimawi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02074878: Clinical Trial Phase 1 study, sponsored by Mothaffar Rimawi.
NCT02074878 is a Phase 1 study that was terminated before completion, run by Mothaffar Rimawi. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02074878, a Phase 1 study, was terminated before completion, sponsored by Mothaffar Rimawi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase 1 Trial. Crizotinib is a medication that is taken by mouth. It has shown that it can help slow down or stop the growth of tumor cells. The marketing name of the drug is "Xalkori". It has been approved by the FDA (Food and Drug Administration) to treat other types of metastatic cancer, but the investigators believe it may be helpful to treat breast cancer as well. Sunitinib is the other medication used in the study. It is also taken by mouth in the form of a capsule. The marketing name of this drug is "Sutent". It too has been approved by the FDA to treat other types of cancer, but not for breast cancer. In this study the investigators will be combining both of these two treatments, but at different doses. One third of the patients will take Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day. One third of the patients will take Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day, and One third of the patients will take Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day.
Primary Outcome
To determine the tolerability of the combination of crizotinib and sunitinib in the treatment of women with metastatic breast cancer (MBC). - This is done by identifying the maximum tolerated dose (MTD) for future phase II studies of the combination of crizotinib and sunitinib.
Interventions
- DRUG Crixotinib 200 mg and Sunitinib Cohort 1
- DRUG Crixotinib 250 mg and Sunitinib Cohort 2
- DRUG Crizotinib & Sunitinib 37.5 mg Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-05-16 |
| Phase | Phase 1 |
Why NCT02074878 stopped before completion
NCT02074878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Crixotinib 200 mg and Sunitinib Cohort 1 is the first listed.
NCT02074878 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02074878 about?
NCT02074878 is a clinical study titled "CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer". This is a Phase 1 Trial. Crizotinib is a medication that is taken by mouth. It has shown that it can help slow down or stop the growth of tumor cells. The marketing name of the drug is "Xalkori". It has been approved by the FDA (Food and Drug Administration) to treat other types of metastatic cancer...
What is the current status of trial NCT02074878?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-06. Estimated completion is 2017-05-16.
What interventions are being tested in trial NCT02074878?
The interventions under investigation include: Crixotinib 200 mg and Sunitinib Cohort 1 (DRUG), Crixotinib 250 mg and Sunitinib Cohort 2 (DRUG), Crizotinib & Sunitinib 37.5 mg Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT02074878?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02074878's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia